DDInter223 DDInter1676
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bosentan {u} (Compound) binds {v} (Gene) EDNRA
Bosentan {u} (Compound) downregulates {v} (Gene) PSMB8
Bosentan {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Bosentan {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Bosentan (Compound) binds EDNRA (Gene)
Bosentan (Compound) downregulates PSMB8 (Gene)
Bosentan (Compound) causes Hepatobiliary disease (Side Effect)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Bosentan may lead to a major life threatening interaction when taken with Encorafenib